𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ropinirole for the treatment of early Parkinson's disease

✍ Scribed by Adler, C. H.; Sethi, K. D.; Hauser, R. A.; Davis, T. L.; Hammerstad, J. P.; Bertoni, J.; Taylor, R. L.; Sanchez-Ramos, J.; O'Brien, C. F.

Book ID
125443836
Publisher
Lippincott Williams and Wilkins
Year
1997
Tongue
English
Weight
773 KB
Volume
49
Category
Article
ISSN
0028-3878

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A comparison of sumanirole versus placeb
A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease
✍ Carlos Singer; Janice Lamb; Amanda Ellis; Gary Layton πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 1 views

## Abstract To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo.

Early treatment benefits of ropinirole p
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
✍ Bonnie P. Hersh; Nancy L. Earl; Robert A. Hauser; Mark Stacy πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 488 KB πŸ‘ 1 views

A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn